June 14, 2014
Below are current clinical trials.1 studies in Polycystic kidney disease
(open studies only).
Filter this list of studies by location, status and more.
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
Study type: Observational What is this?
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
About this study
This Pilot study will enable development & assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
Print study details
- Rochester, Minnesota: 14-003832
NCT ID: NCT02173080
Sponsor Protocol Number: 14-003832
- Polycystic kidney disease. National Kidney and Urologic Diseases Information Clearinghouse. http://kidney.niddk.nih.gov/kudiseases/pubs/polycystic/. Accessed March 29, 2014.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2014. https://www.clinicalkey.com. Accessed March 29, 2014.
- Alpern RJ, et al. Seldin and Giebisch's The Kidney. 5th ed. Philadelphia, Pa.: Elsevier; 2013. http://www.clinicalkey.com. Accessed March 29, 2014.
- Polycystic kidney disease. Kidney Foundation. http://www.kidney.org/atoz/content/polycystic.cfm . Accessed March 29, 2014.
- Taal MW, et al. Brenner & Rector's The Kidney. 9th ed. Philadelphia, Pa.: Saunders Elsevier; 2011. http://www.clinicalkey.com. Accessed March 29, 2014.
- Riggin EA. Decision Support System. Mayo Clinic, Rochester, Minn. Feb. 26, 2014.
- Devuyst O, et al. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Current Opinion in Nephrology and Hypertension. 2013;22:459.
- Rossetti S, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. Journal of the American Society of Nephrology. 2012;23:915.
- Torres VE, et al. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. Journal of the American Society of Nephrology. 2014; 25:18.
- Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine. 2012;367:2407.
- Hogan MC, et al. Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years. Nephrology Dialysis Transplantation. 2012;27:3532.
- Castle EP (expert opinion). Mayo Clinic, Phoenix /Scottsdale, Ariz. April 6, 2014.
- Heilman RL (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. April 7, 2014.